

GenCore version 5.1.6
Copyright (c) 1993 - 2005 Compugen Ltd.

OM nucleic - nucleic search, using sw model

Run on: January 31, 2005, 16:14:26 ; Search time 0.001 Seconds
(without alignments)
537.732 Million cell updates/sec

Title: us-10-063-553-47
Perfect score: 766
Sequence: 1 ggctcgagcgtttcttgagcc.....agtagtttgaaaaaaa 766

Scoring table: IDENTITY_NUC
Gapop 10.0 , Gapext 0.5

Searched: 1 segs, 351 residues

Total number of hits satisfying chosen parameters: 2

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : us-09-803-719-950:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	265.2	34.6	351	1	us-09-803-719-950
2	21.6	2.8	351	1	us-09-803-719-950

ALIGNMENTS

RESULT 1
us-09-803-719-950

Query Match		34.6%;	Score 265.2;	DB 1;	Length 351;
Best Local Similarity		91.0%;	Pred. No. 0;		
Matches 303;		Conservative 0;	Mismatches 28;	Indels 2;	Gaps 2;
Qy	7	AGCGTTTCTGAGCCAGGGGTGACCATGACCTGCTGCGAAGGATGGACATCCTGCAATGGA	66		
Db	18	AACGCTCCTGTGCCATGCGTGACCATGACCTGCTGATAAGGATGGACATCCTGCCTAGTA	77		
Qy	67	TTCAGCCTGCTGGTTCTACTGCTGTTAGGAGTAGTTCTCAATGCGATACCT-CTAATTGT	125		
Db	78	CTCAACCTGCTGCCCTTTACTGCTGGTAGGAGTCGTTCTCACTGCGACACCTGCTAATTGT	137		
Qy	126	CAGCTTACTT-GAGGAAGACCAATTTTCTCAAACCCCATCTCTTGCTTTGAGTGGTGGT	184		
Db	138	CATATTATTAGAGGAAGACCAATTGTCTCAAAGCCCATCTCTTGCTTTGAGTGGTGGT	197		
Qy	185	TCCCAGGAATTATAGGAGCAGGTCTGATGGCCATTCAGCAACAACATGTCCTTGACAG	244		
Db	198	TCCACGAATTATAGGAGCAGGTCTGATGGCCATTCAGCAACAACATGTCCTTGACAG	257		
Qy	245	CAAGAAAAGAGCGTGTGCAACAACAGAACTGGAATGTTCTTTTCATCATTTTTCAGTG	304		
Db	258	CAAGAAAAGAGCGTGTGCAACAACAGAACTGGAATGTTCTTTTCATCATTTTTCAGTG	317		

Qy	305	TGATCACAGTCATTGGTGTCTCTGTATTGCATGC	337																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																								
----	-----	------------------------------------	-----	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--

Search completed: January 31, 2005, 16:14:26
Job time : 0.001 secs

This Page Blank (uspto)

This Page Blank (uspto)

GenCore version 5.1.6
Copyright (c) 1993 - 2005 Compugen Ltd.

OM nucleic - nucleic search, using sw model

Run on: January 31, 2005, 16:18:13 ; Search time 0.001 Seconds
(without alignments)
438.152 Million cell updates/sec

Title: us-10-063-553-47
Perfect score: 766
Sequence: 1 ggctcgagcgtttcttgagcc.....agtagttgaaaaa 766

Scoring table: IDENTITY_NUC
Gapop 10.0 , Gapext 0.5

Searched: 1 seqs, 286 residues

Total number of hits satisfying chosen parameters: 2

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : aaf98695.geneseqn2001bs:*

Pred. No. is the number of results predicted by chance to have a
score greater than or equal to the score of the result being printed,
and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	231.4	30.2	286	1 AAF98695	Human ovarian canc
2	16.6	2.2	286	1 AAF98695	Human ovarian canc

ALIGNMENTS

RESULT 1
AAF98695
ID AAF98695 standard; DNA; 286 BP.
XX
AC AAF98695;
XX
DT 02-JUL-2001 (first entry)
XX
DE Human ovarian cancer cell expressed sequence 10793.
XX
KW Human; ovarian cancer; identification; detection; characterisation;
KW tumour; kinase; marker; cytostatic; antisense gene therapy; ds.
XX
OS Homo sapiens.
XX
PN WO200118542-A2.
XX
PD 15-MAR-2001.
XX
PF 01-SEP-2000; 2000WO-US024199.
XX
PR 03-SEP-1999; 99US-0152547P.
PR 16-MAR-2000; 2000US-0190347P.
PR 21-MAR-2000; 2000US-0191321P.
PR 31-MAY-2000; 2000US-0208382P.
PR 20-JUL-2000; 2000US-00220467.

XX (MILL-) MILLENNIUM PREDICTIVE MEDICINE INC.
PA
XX
PI Lee J, Thompsho P, Lillie J;
XX
DR WPI; 2001-211428/21.
XX
PT Detection, assessment, prevention and therapy of ovarian cancer,
PT comprises detecting changes in the expression of a variety of markers.
XX
PS Claim 1; Page 998-999; 1198pp; English.
XX
CC The present invention describes a method for assessing whether a patient
CC is afflicted with ovarian cancer by comparing: (1) the expression of a
CC marker (I) (see AAF98594 to AAF98730), in a patient sample; and (2) the
CC normal level of expression of (I) in a control non-ovarian cancer sample,
CC where a significant difference between the level of expression in (a) and
CC (b) is an indication that the patient is afflicted with ovarian cancer.
CC (I) have cytostatic activities and can be used in antisense gene therapy.
CC The method, compositions and kits from the present invention can be used
CC for: (1) assessing and treating ovarian cancer; (2) making isolated
CC hybridoma, which produces an antibody useful for ovarian cancer
CC assessment; and (3) inhibiting ovarian cancer in a patient. AAF98573 to
CC AAF98593 represent human kinase marker primers and probes which are used
CC in the exemplification of the present invention
XX
SQ Sequence 286 BP; 65 A; 69 C; 76 G; 76 T; 0 U; 0 Other;
Query Match 30.2%; Score 231.4; DB 1; Length 286;
Best Local Similarity 99.6%; Pred. No. 0;
Matches 232; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
Qy 7 AGCGTTCTGAGCCAGGGGTGACCATGACCTGCTGCGAAGGATGGACATCCTGCAATGGA 66
Db ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
48 AACGTTTCTGAGCCAGGGGTGACCATGACCTGCTGCGAAGGATGGACATCCTGCAATGGA 107
Qy 67 TTCAGCCTGCTGTTTCTACTGCTGTTAGGAGTAGTTCTCAATGCGATACCTCTAATTGTC 126
Db ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
108 TTCAGCCTGCTGTTTCTACTGCTGTTAGGAGTAGTTCTCAATGCGATACCTCTAATTGTC 167
Qy 127 AGCTTAGTTGAGGAACCAATTTTCTCAAAACCCCATCTCTTGTGTTGAGTGGTGTTC 186
Db ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
168 AGCTTAGTTGAGGAACCAATTTTCTCAAAACCCCATCTCTTGTGTTGAGTGGTGTTC 227
Qy 187 CCAGGAATTATAGGACAGGTCTGATGGCCATTCCAGCAACAACAATGTCCTT 239
Db ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
228 CCAGGAATTATAGGACAGGTCTGATGGCCATTCCAGCAACAACAATGTCCTT 280
RESULT 2
AAF98695/c
ID AAF98695 standard; DNA; 286 BP.
XX
AC AAF98695;
XX
DT 02-JUL-2001 (first entry)
XX
DE Human ovarian cancer cell expressed sequence 10793.
XX
KW Human; ovarian cancer; identification; detection; characterisation;
KW tumour; kinase; marker; cytostatic; antisense gene therapy; ds.
XX
OS Homo sapiens.
XX
PN WO200118542-A2.
XX
PD 15-MAR-2001.
XX
PF 01-SEP-2000; 2000WO-US024199.
XX
PR 03-SEP-1999; 99US-0152547P.
PR 16-MAR-2000; 2000US-0190347P.
PR 21-MAR-2000; 2000US-0191321P.
PR 31-MAY-2000; 2000US-0208382P.
PR 20-JUL-2000; 2000US-00220467.

PR 31-MAY-2000; 2000US-0208382P.
PR 20-JUL-2000; 2000US-00220467.
XX
PA (MILL-) MILLENNIUM PREDICTIVE MEDICINE INC.
XX
PI Lee J, Thompson P, Lillie J;
XX
DR WPI; 2001-211428/21.
XX
PT Detection, assessment, prevention and therapy of ovarian cancer,
PT comprises detecting changes in the expression of a variety of markers.
XX
PS Claim 1; Page 998-999; 1198pp; English.
XX
CC The present invention describes a method for assessing whether a patient
CC is afflicted with ovarian cancer by comparing: (1) the expression of a
CC marker (I) (see AAF98594 to AAF98730), in a patient sample; and (2) the
CC normal level of expression of (I) in a control non-ovarian cancer sample,
CC where a significant difference between the level of expression in (a) and
CC (b) is an indication that the patient is afflicted with ovarian cancer.
CC (I) have cytostatic activities and can be used in antisense gene therapy.
CC The method, compositions and kits from the present invention can be used
CC for: (1) assessing and treating ovarian cancer; (2) making isolated
CC hybridoma, which produces an antibody useful for ovarian cancer
CC assessment; and (3) inhibiting ovarian cancer in a patient. AAF98573 to
CC AAF98593 represent human kinase marker primers and probes which are used
CC in the exemplification of the present invention
XX
SQ Sequence 286 BP; 65 A; 69 C; 76 G; 76 T; 0 U; 0 Other;

Query Match 2.2%; Score 16.6; DB 1; Length 286;
Best Local Similarity 52.1%; Pred. No. 0;
Matches 37; Conservative 0; Mismatches 34; Indels 0; Gaps 0;

QY 359 TAAAGGTCCTCTCATGTGTAAATCTCCAAGCAACAGTAATGCCAATTGTGAATTTTCAT 418
Db 162 TTAGAGTATCGCAATTGAGAACTACTCCTAACACAGTAGAACCCAGCAGGCTGAATCCAT 103

QY 419 TGAACAAACATC 429
Db 102 TGCAGGATGTC 92

Search completed: January 31, 2005, 16:18:13
Job time : 0.001 secs

GenCore version 5.1.6
Copyright (c) 1993 - 2005 Compugen Ltd.

OM nucleic - nucleic search, using sw model

Run on: January 31, 2005, 16:16:07 ; Search time 0.001 Seconds
(without alignments)
1124.488 Million cell updates/sec

Title: us-10-063-553-47
Perfect score: 766
Sequence: 1 ggctcgagcgtttctgagcc.....agtagtttgaaaaaaaaa 766

Scoring table: IDENTITY NUC
Gapop 10.0 , Gapext 0.5

Searched: 1 seqs, 734 residues

Total number of hits satisfying chosen parameters: 2

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : aak88578.geneseqn200las:*

Pred. No. is the number of results predicted by chance to have a
score greater than or equal to the score of the result being printed,
and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Query		DB ID	Description
	Score	Match Length		
1	430.1	56.1	734 1 AAK88578	Human digestive sy
2	19	2.5	734 1 AAK88578	Human digestive sy

ALIGNMENTS

RESULT 1
AAK88578
ID AAK88578 standard; cDNA; 734 BP.
XX
AC AAK88578;
XX
DT 05-NOV-2001 (first entry)
XX
DE Human digestive system antigen coding sequence SEQ ID NO: 894.
XX
KW Human; digestive system antigen; gene therapy; cancer; appendicitis;
KW ulcerative colitis; infection; Hirschsprung's disease; chronic colitis;
KW digestive system disorder; Meckel's diverticulum; ss.
XX
OS Homo sapiens.
XX
PN WO200155314-A2.
XX
PD 02-AUG-2001.
XX
PF 17-JAN-2001; 2001WO-US001324.
XX
PR 31-JAN-2000; 2000US-0179065P.
PR 04-FEB-2000; 2000US-0180628P.
PR 24-FEB-2000; 2000US-0184664P.
PR 02-MAR-2000; 2000US-0186350P.

PR 16-MAR-2000; 2000US-0189874P.
PR 17-MAR-2000; 2000US-0190076P.
PR 18-APR-2000; 2000US-0198123P.
PR 19-MAY-2000; 2000US-0205515P.
PR 07-JUN-2000; 2000US-0209467P.
PR 28-JUN-2000; 2000US-0214886P.
PR 30-JUN-2000; 2000US-0215135P.
PR 07-JUL-2000; 2000US-0216647P.
PR 07-JUL-2000; 2000US-0216880P.
PR 11-JUL-2000; 2000US-0217487P.
PR 11-JUL-2000; 2000US-0217496P.
PR 14-JUL-2000; 2000US-0218290P.
PR 26-JUL-2000; 2000US-0220963P.
PR 26-JUL-2000; 2000US-0220964P.
PR 14-AUG-2000; 2000US-0224518P.
PR 14-AUG-2000; 2000US-0224519P.
PR 14-AUG-2000; 2000US-0225213P.
PR 14-AUG-2000; 2000US-0225214P.
PR 14-AUG-2000; 2000US-0225266P.
PR 14-AUG-2000; 2000US-0225267P.
PR 14-AUG-2000; 2000US-0225268P.
PR 14-AUG-2000; 2000US-0225270P.
PR 14-AUG-2000; 2000US-0225447P.
PR 14-AUG-2000; 2000US-0225757P.
PR 14-AUG-2000; 2000US-0225758P.
PR 14-AUG-2000; 2000US-0225759P.
PR 18-AUG-2000; 2000US-0226279P.
PR 22-AUG-2000; 2000US-0226681P.
PR 22-AUG-2000; 2000US-0226868P.
PR 22-AUG-2000; 2000US-0227182P.
PR 23-AUG-2000; 2000US-0227009P.
PR 30-AUG-2000; 2000US-0228924P.
PR 01-SEP-2000; 2000US-0229287P.
PR 01-SEP-2000; 2000US-0229343P.
PR 01-SEP-2000; 2000US-0229344P.
PR 01-SEP-2000; 2000US-0229345P.
PR 05-SEP-2000; 2000US-0229509P.
PR 05-SEP-2000; 2000US-0229513P.
PR 06-SEP-2000; 2000US-0230437P.
PR 06-SEP-2000; 2000US-0230438P.
PR 08-SEP-2000; 2000US-0231242P.
PR 08-SEP-2000; 2000US-0231243P.
PR 08-SEP-2000; 2000US-0231244P.
PR 08-SEP-2000; 2000US-0231413P.
PR 08-SEP-2000; 2000US-0231414P.
PR 08-SEP-2000; 2000US-0232080P.
PR 08-SEP-2000; 2000US-0232081P.
PR 12-SEP-2000; 2000US-0231968P.
PR 14-SEP-2000; 2000US-0232397P.
PR 14-SEP-2000; 2000US-0232398P.
PR 14-SEP-2000; 2000US-0232399P.
PR 14-SEP-2000; 2000US-0232400P.
PR 14-SEP-2000; 2000US-0232401P.
PR 14-SEP-2000; 2000US-0233063P.
PR 14-SEP-2000; 2000US-0233064P.
PR 14-SEP-2000; 2000US-0233065P.
PR 21-SEP-2000; 2000US-0234223P.
PR 21-SEP-2000; 2000US-0234274P.
PR 25-SEP-2000; 2000US-0234997P.
PR 25-SEP-2000; 2000US-0234998P.
PR 26-SEP-2000; 2000US-0235484P.
PR 27-SEP-2000; 2000US-0235834P.
PR 27-SEP-2000; 2000US-0235836P.
PR 29-SEP-2000; 2000US-0236327P.
PR 29-SEP-2000; 2000US-0236367P.
PR 29-SEP-2000; 2000US-0236368P.
PR 29-SEP-2000; 2000US-0236369P.
PR 29-SEP-2000; 2000US-0236370P.
PR 02-OCT-2000; 2000US-0236802P.
PR 02-OCT-2000; 2000US-0237037P.
PR 02-OCT-2000; 2000US-0237038P.
PR 02-OCT-2000; 2000US-0237039P.
PR 02-OCT-2000; 2000US-0237040P.

PR 13-OCT-2000; 2000US-0239935P.
PR 13-OCT-2000; 2000US-0239937P.
PR 20-OCT-2000; 2000US-0240960P.
PR 20-OCT-2000; 2000US-0241221P.
PR 20-OCT-2000; 2000US-0241785P.
PR 20-OCT-2000; 2000US-0241786P.
PR 20-OCT-2000; 2000US-0241787P.
PR 20-OCT-2000; 2000US-0241808P.
PR 20-OCT-2000; 2000US-0241809P.
PR 20-OCT-2000; 2000US-0241826P.
PR 01-NOV-2000; 2000US-0244617P.
PR 08-NOV-2000; 2000US-0246474P.
PR 08-NOV-2000; 2000US-0246475P.
PR 08-NOV-2000; 2000US-0246476P.
PR 08-NOV-2000; 2000US-0246524P.
PR 08-NOV-2000; 2000US-0246525P.
PR 08-NOV-2000; 2000US-0246526P.
PR 08-NOV-2000; 2000US-0246527P.
PR 08-NOV-2000; 2000US-0246528P.
PR 08-NOV-2000; 2000US-0246532P.
PR 08-NOV-2000; 2000US-0246609P.
PR 08-NOV-2000; 2000US-0246610P.
PR 08-NOV-2000; 2000US-0246611P.
PR 08-NOV-2000; 2000US-0246613P.
PR 17-NOV-2000; 2000US-0249207P.
PR 17-NOV-2000; 2000US-0249208P.
PR 17-NOV-2000; 2000US-0249209P.
PR 17-NOV-2000; 2000US-0249210P.
PR 17-NOV-2000; 2000US-0249211P.
PR 17-NOV-2000; 2000US-0249212P.
PR 17-NOV-2000; 2000US-0249213P.
PR 17-NOV-2000; 2000US-0249214P.
PR 17-NOV-2000; 2000US-0249215P.
PR 17-NOV-2000; 2000US-0249216P.
PR 17-NOV-2000; 2000US-0249217P.
PR 17-NOV-2000; 2000US-0249218P.
PR 17-NOV-2000; 2000US-0249244P.
PR 17-NOV-2000; 2000US-0249245P.
PR 17-NOV-2000; 2000US-0249264P.
PR 17-NOV-2000; 2000US-0249265P.
PR 17-NOV-2000; 2000US-0249297P.
PR 17-NOV-2000; 2000US-0249299P.
PR 17-NOV-2000; 2000US-0249300P.
PR 01-DEC-2000; 2000US-0250160P.
PR 01-DEC-2000; 2000US-0250391P.
PR 05-DEC-2000; 2000US-0251030P.
PR 05-DEC-2000; 2000US-0251988P.
PR 05-DEC-2000; 2000US-0256719P.
PR 06-DEC-2000; 2000US-0251479P.
PR 08-DEC-2000; 2000US-0251856P.
PR 08-DEC-2000; 2000US-0251868P.
PR 08-DEC-2000; 2000US-0251869P.
PR 08-DEC-2000; 2000US-0251989P.
PR 08-DEC-2000; 2000US-0251990P.
PR 11-DEC-2000; 2000US-0254097P.
PR 05-JAN-2001; 2001US-0259678P.
XX
PA (HUMA-) HUMAN GENOME SCI INC.
XX
XX
PI Rosen CA, Barash SC, Ruben SM;
XX
XX
DR WPI; 2001-502630/55.
DR P-PSDB; AAM92805.
XX
PT Polynucleotides encoding digestive system antigens, useful for
PT diagnosing, treating, preventing and/or prognosing disorders of the
PT digestive system, particularly cancer and cancer metastases.
XX
XX
PS Claim 1; SEQ ID NO 894; 986pp; English.
XX

CC The present invention provides the protein and coding sequences of a
CC number of human digestive system antigens. These can be used in the
CC diagnosis, treatment and prevention of digestive system disorders,
CC including cancer, Meckel's diverticulum, bacterial or parasitic
CC infections, appendicitis, Hirschsprung's disease, chronic colitis or
CC ulcerative colitis. The present sequence is a cDNA encoding a digestive
CC system antigen of the invention
XX
SQ Sequence 734 BP; 214 A; 124 C; 155 G; 233 T; 0 U; 8 Other;
Query Match 56.1%; Score 430.1; DB 1; Length 734;
Best Local Similarity 98.7%; Pred.No. 0;
Matches 440; Conservative 3; Mismatches 2; Indels 1; Gaps 1;
QY 317 TTGGTGCTCTGTATTGCAATGCTGATATCCATCCAGGCTCTCTTAAAGGTCCTCTCATGT 376
Db 1 TTGGTGCTCTGTATTGCAATGCTGATATCCATCCAGGCTCTCTTAAAGGTCCTCTCATGT 60
QY 377 GTAATTCTCCAAGCAACAGTAATGCCAATTTTCAATTTGAAAAACATCAGTGACA 436
Db 61 GTAATTCTCCAAGCAACAGTAATGCCAATTTTCAATTTGAAAAACATCAGTGACA 120
QY 437 TTCATCCAGAATCCTTCAACTTGCAATGCTGATTTTCAATGACTTTGTGCACCTCTACTG 496
Db 121 TTCATCCAGAATCCTTCAACTTGCAATGCTGATTTTCAATGACTTTGTGCACCTCTACTG 180
QY 497 GTTTCATTAACCCACCAAGTAACGACACCATGGCGAGTGGCTGGAGAGCATCTAGTTTCC 556
Db 181 GTTTCATTAACCCACCAAGTAACGACACCATGGCGAGTGGCTGGAGAGCATCTAGTTTCC 240
QY 557 ACTTCGATTCTGAAGAAACAAACATAGGCTTATCCACTTCTCAGTATTTTGGTCTAT 616
Db 241 ACTTCGATTCTGAAGAAACAAACATAGGCTTATCCACTTCTCAGTATTTTGGTCTAT 300
QY 617 TGCTTGTGGAAATCTGGAGGCTCTGTTGGGCTCAGTCAGATAGTCATCGGTTTCTT- 675
Db 301 TGCTTGTGGAAATCTGGAGGCTCTGTTGGGCTCAGTCAGATAGTCATCGGTTTCTT- 360
QY 676 GGCTGCTGTGTGGAGTCTTAAGCGAAGAGTCAAATTTGTAGTTTAATGGGAATAAA 735
Db 361 GGCKGTCGTGTGGAGTCTTAAGCGAAGAGTCAAATTTGTAGTTTAATGGGAATAAA 420
QY 736 ATGTAAGTATCAGTAGTTTGAATAAA 761
Db 421 ATGTAAGTATCAGTAGTTTGAATAAA 446
RESULT 2
AAK88578/c
ID AAK88578 standard; cDNA; 734 BP.
XX
AC AAK88578;
XX
DT 05-NOV-2001 (first entry)
XX
DE Human digestive system antigen coding sequence SEQ ID NO: 894.
XX
KW Human; digestive system antigen; gene therapy; cancer; appendicitis;
KW ulcerative colitis; infection; Hirschsprung's disease; chronic colitis;
KW digestive system disorder; Meckel's diverticulum; ss.
XX
OS Homo sapiens.
XX
PN WO200155314-A2.
XX
PD 02-AUG-2001.
XX
PF 17-JAN-2001; 2001WO-US0001324.
XX
PR 31-JAN-2000; 2000US-0179065P.
PR 04-FEB-2000; 2000US-0180628P.
PR 24-FEB-2000; 2000US-0184664P.
PR 02-MAR-2000; 2000US-0186350P.

PR 16-MAR-2000; 2000US-0189874P.
PR 17-MAR-2000; 2000US-0190076P.
PR 18-APR-2000; 2000US-0198123P.
PR 19-MAY-2000; 2000US-0205515P.
PR 07-JUN-2000; 2000US-0209467P.
PR 28-JUN-2000; 2000US-0214886P.
PR 30-JUN-2000; 2000US-0215135P.
PR 07-JUL-2000; 2000US-0216647P.
PR 07-JUL-2000; 2000US-0216880P.
PR 11-JUL-2000; 2000US-0217487P.
PR 11-JUL-2000; 2000US-0217496P.
PR 14-JUL-2000; 2000US-0218290P.
PR 26-JUL-2000; 2000US-0220963P.
PR 26-JUL-2000; 2000US-0220964P.
PR 14-AUG-2000; 2000US-0224518P.
PR 14-AUG-2000; 2000US-0225211P.
PR 14-AUG-2000; 2000US-0225214P.
PR 14-AUG-2000; 2000US-0225266P.
PR 14-AUG-2000; 2000US-0225267P.
PR 14-AUG-2000; 2000US-0225268P.
PR 14-AUG-2000; 2000US-0225270P.
PR 14-AUG-2000; 2000US-0225447P.
PR 14-AUG-2000; 2000US-0225757P.
PR 14-AUG-2000; 2000US-0225758P.
PR 14-AUG-2000; 2000US-0225759P.
PR 18-AUG-2000; 2000US-0226681P.
PR 22-AUG-2000; 2000US-0226279P.
PR 22-AUG-2000; 2000US-0226868P.
PR 22-AUG-2000; 2000US-0227182P.
PR 23-AUG-2000; 2000US-0227009P.
PR 30-AUG-2000; 2000US-0228924P.
PR 01-SEP-2000; 2000US-0229287P.
PR 01-SEP-2000; 2000US-0229343P.
PR 01-SEP-2000; 2000US-0229344P.
PR 01-SEP-2000; 2000US-0229345P.
PR 05-SEP-2000; 2000US-0229509P.
PR 05-SEP-2000; 2000US-0229513P.
PR 06-SEP-2000; 2000US-0230437P.
PR 06-SEP-2000; 2000US-0230438P.
PR 08-SEP-2000; 2000US-0231242P.
PR 08-SEP-2000; 2000US-0231243P.
PR 08-SEP-2000; 2000US-0231244P.
PR 08-SEP-2000; 2000US-0231413P.
PR 08-SEP-2000; 2000US-0231414P.
PR 08-SEP-2000; 2000US-0232080P.
PR 08-SEP-2000; 2000US-0232081P.
PR 12-SEP-2000; 2000US-0231968P.
PR 14-SEP-2000; 2000US-0232397P.
PR 14-SEP-2000; 2000US-0232398P.
PR 14-SEP-2000; 2000US-0232399P.
PR 14-SEP-2000; 2000US-0232400P.
PR 14-SEP-2000; 2000US-0232401P.
PR 14-SEP-2000; 2000US-0233063P.
PR 14-SEP-2000; 2000US-0233064P.
PR 14-SEP-2000; 2000US-0233065P.
PR 21-SEP-2000; 2000US-0234223P.
PR 21-SEP-2000; 2000US-0234274P.
PR 25-SEP-2000; 2000US-0234997P.
PR 25-SEP-2000; 2000US-0234998P.
PR 26-SEP-2000; 2000US-0235484P.
PR 27-SEP-2000; 2000US-0235834P.
PR 27-SEP-2000; 2000US-0235836P.
PR 29-SEP-2000; 2000US-0236327P.
PR 29-SEP-2000; 2000US-0236367P.
PR 29-SEP-2000; 2000US-0236368P.
PR 29-SEP-2000; 2000US-0236369P.
PR 29-SEP-2000; 2000US-0236370P.
PR 02-OCT-2000; 2000US-0236802P.
PR 02-OCT-2000; 2000US-0237037P.
PR 02-OCT-2000; 2000US-0237038P.
PR 02-OCT-2000; 2000US-0237039P.
PR 02-OCT-2000; 2000US-0237040P.

PR 13-OCT-2000; 2000US-0239935P.
PR 13-OCT-2000; 2000US-0239937P.
PR 20-OCT-2000; 2000US-0240960P.
PR 20-OCT-2000; 2000US-0241221P.
PR 20-OCT-2000; 2000US-0241785P.
PR 20-OCT-2000; 2000US-0241786P.
PR 20-OCT-2000; 2000US-0241787P.
PR 20-OCT-2000; 2000US-0241808P.
PR 20-OCT-2000; 2000US-0241809P.
PR 20-OCT-2000; 2000US-0241826P.
PR 01-NOV-2000; 2000US-0244617P.
PR 08-NOV-2000; 2000US-0246474P.
PR 08-NOV-2000; 2000US-0246475P.
PR 08-NOV-2000; 2000US-0246476P.
PR 08-NOV-2000; 2000US-0246477P.
PR 08-NOV-2000; 2000US-0246523P.
PR 08-NOV-2000; 2000US-0246524P.
PR 08-NOV-2000; 2000US-0246525P.
PR 08-NOV-2000; 2000US-0246526P.
PR 08-NOV-2000; 2000US-0246527P.
PR 08-NOV-2000; 2000US-0246528P.
PR 08-NOV-2000; 2000US-0246532P.
PR 08-NOV-2000; 2000US-0246609P.
PR 08-NOV-2000; 2000US-0246610P.
PR 08-NOV-2000; 2000US-0246611P.
PR 08-NOV-2000; 2000US-0246613P.
PR 17-NOV-2000; 2000US-0249207P.
PR 17-NOV-2000; 2000US-0249208P.
PR 17-NOV-2000; 2000US-0249209P.
PR 17-NOV-2000; 2000US-0249210P.
PR 17-NOV-2000; 2000US-0249211P.
PR 17-NOV-2000; 2000US-0249212P.
PR 17-NOV-2000; 2000US-0249213P.
PR 17-NOV-2000; 2000US-0249214P.
PR 17-NOV-2000; 2000US-0249215P.
PR 17-NOV-2000; 2000US-0249216P.
PR 17-NOV-2000; 2000US-0249217P.
PR 17-NOV-2000; 2000US-0249218P.
PR 17-NOV-2000; 2000US-0249244P.
PR 17-NOV-2000; 2000US-0249245P.
PR 17-NOV-2000; 2000US-0249264P.
PR 17-NOV-2000; 2000US-0249265P.
PR 17-NOV-2000; 2000US-0249297P.
PR 17-NOV-2000; 2000US-0249299P.
PR 17-NOV-2000; 2000US-0249300P.
PR 01-DEC-2000; 2000US-0250160P.
PR 01-DEC-2000; 2000US-0250391P.
PR 05-DEC-2000; 2000US-0251030P.
PR 05-DEC-2000; 2000US-0251988P.
PR 05-DEC-2000; 2000US-0256719P.
PR 06-DEC-2000; 2000US-0251479P.
PR 08-DEC-2000; 2000US-0251856P.
PR 08-DEC-2000; 2000US-0251868P.
PR 08-DEC-2000; 2000US-0251869P.
PR 08-DEC-2000; 2000US-0251989P.
PR 08-DEC-2000; 2000US-0251990P.
PR 11-DEC-2000; 2000US-0254097P.
PR 05-JAN-2001; 2001US-0259678P.

(HUMA-) HUMAN GENOME SCI INC.

Rosen CA, Barash SC, Ruben SM;

WPI; 2001-502630/55.

P-PSDB; AAM92805.

Polynucleotides encoding digestive system antigens, useful for
diagnosing, treating, preventing and/or prognosing disorders of the
digestive system, particularly cancer and cancer metastases.

Claim 1; SEQ ID NO 894; 986pp; English.

CC The present invention provides the protein and coding sequences of a
CC number of human digestive system antigens. These can be used in the
CC diagnosis, treatment and prevention of digestive system disorders,
CC including cancer, Meckel's diverticulum, bacterial or parasitic
CC infections, appendicitis, Hirschsprung's disease, chronic colitis or
CC ulcerative colitis. The present sequence is a cDNA encoding a digestive
CC system antigen of the invention
XX

SQ Sequence 734 BP; 214 A; 124 C; 155 G; 233 T; 0 U; 8 Other;

Query Match 2.5%; Score 19; DB 1; Length 734;
Best Local Similarity 51.8%; Pred. No. 0;
Matches 43; Conservative 0; Mismatches 40; Indels 0; Gaps 0;

QY	394	AGTAATGCCAATGTGAAATTTTCATTGAAAAACATCAGTGACATTCATCCAGAACTCTTC	453
Db	489	AATCATCTCAAGATGACTTTGAAAAACAAGTGACTTCTCAAATTAATTCAAACTACTGA	430
QY	454	AACTTGCAGTGGTTTTTCAATGA	476
Db	429	TACTTACATTTTATCCCATTA	407

Search completed: January 31, 2005, 16:16:08
Job time : 1 secs

GenCore version 5.1.6
Copyright (c) 1993 - 2005 Compugen Ltd.

OM nucleic - nucleic search, using sw model

Run on: January 31, 2005, 16:17:18 ; Search time 0.001 Seconds
(without alignments)
537.732 Million cell updates

```

Title:          us-10-063-553-47
Perfect score:  766
Sequence:       1 ggctcgagcgtttcttgagcc.....agtagttgaaaaaaaaaa 766

```

Scoring table: IDENTITY_NUC
Gapop 10.0 , Gapext 0.5

Searched: 1 seqs, 351 residues

Total number of hits satisfying chosen parameters: 2

```
Minimum DB seq length: 0
Maximum DB seq length: 2000000000
```

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : aas37892.geneseqn2001as:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

Result No.	%			DB	ID	Description
	Score	Match	Length			
1	265.2	34.6	351	1	AAS37892	Novel human diagno
C 2	21.6	2.8	351	1	AAS37892	Novel human diagno

ALIGNMENTS

RESULT 1
AAS37892
ID AAS37892 standard; cDNA; 351 BP.

AA	
AC	AAS37892;
XX	
XX	17-DEC-2001 (first entry)
XX	
DE	Novel human diagnostic and therapeutic gene #950.

Human; cancer; breast; lung; colon; prostate; cytostatic; diagnostic; ss.

OS Homo sapiens.

PN WO200166753-A2.

PD 13-SEP-2001.

09-MAR-2001; 2001WO-US007787.

PR 09-MAR-2000; 2000US-0188609P.

PA (CHIR) CHIRON CORP.

PA (HYSE-) HYSEQ INC.

XX PI Williams LT, Escobedo J, Innis MA, Garcia PD, Sudduth-Klinger J;

PI	Reinhard C, Randazzo F, Kennedy GC, Pot D, .Kassam A, Lamson G;
PI	Drmanac R, Crkvenjakov R, Dickson M, Drmanac S, Labat I;
PI	Leshkowitz D, Kita D, Garcia V, Jones WL, Stache-Crain B;
XX	
DR	WPI; 2001-530177/58.
XX	
XX	New polynucleotides and polypeptides, useful for diagnosis and treatment
PT	of breast, lung and colon cancer.
PT	
XX	
XX	Claim 1; Page 836; 1193pp; English.
PS	
XX	
CC	The invention relates to new polynucleotides and polypeptides, useful for
CC	diagnosis and treatment of breast, lung and colon cancer. The sequences
CC	can be used in detecting differentially expressed genes correlated with a
CC	cancerous state of a mammalian cell, comprising detecting at least one
CC	differentially expressed gene product in a test sample derived from a
CC	cell suspected of being cancerous. They can also be used to inhibit
CC	tumour growth by modulating expression of a gene product. AAS36943-
CC	AAS39338 represent novel human diagnostic and therapeutic coding
CC	sequences of the invention
XX	
SO	Sequence 351 BP; 87 A; 86 C; 80 G; 97 T; 0 U; 1 Other;

Query Match	34.6%	Score 265.2;	DB 1;	Length 351;
Best Local Similarity	91.0%;	Pred. No. 0;		
Matches 303; Conservative	0;	Mismatches 28;	Indels 2;	Gaps 2;

QY 7 AGCGTTTCTGAGCCAGGGGTGACCATGACCTGTCGGAAGGATGGACATCCTGCAATGGA 66
| | | | | | | | | | | | | | | | | | | | | |
Dp 18 AACGCTCCTGTGCCCATCGTGACCATGACCTGCTGATAAGGATGGACATCCTGCCTAGTA 77

QY	67	TTCAGCCTGCTGGTTC	ACTGCTGTAGGAGTAGTTCTCAATGGACACCT-CTAATTGT	125
pb	78	CTCAACCTGTCCTTTACTGCTGGTAGGAGTCGTTCTACCTGGCACACCTGCTAATTGT		137

[illegible]

185 TCCAGGAATTATAGGAGCAGGTCTGATGGCCATTCCAGCAACAACAATGTCCTTGACAG 244
198 TCCACGAAATTATAGGAGCAGGTCTGATGGCCATTCCAGCAACAACAATGTCCTTGACAG 257

Qy	245	CAAGAAAAGAGCGTGTGCAACAAACAGAACTGGAATGTTTCATTTCATCATTTTTCAGTG	304
Db	258	CAAGAAAAGAGCGTGTGCAACAAACAGAACTGGAATGTTTCATTTCATCATTTTTCAGTG	317

QY 305 TGATCACAGTCATTGGTGTCTCTGTATTGCATGC 337
|||||
Db 318 TGATCACAGTCATTGGTGTCTCTGTATTGCATGC 350

RESULT 2
AAS37892/c
ID AAS37892 standard; CDNA; 351 BP.

AC AAS37892;

DT 17-DEC-2001 (first entry)

DE Novel human diagnostic and therapeutic gene #950.

Human; cancer; breast; lung; colon; prostate; cytostatic; diagnostic; ss.
KW

OS Homo sapiens.

PN WO200166753-A2.

PD 13-SEP-2001.

PF 09-MAR-2001; 2001WO-US007787.

PR 09-MAR-2000; 2000US-0188609P.

GenCore version 5.1.6
Copyright (c) 1993 - 2005 Compugen Ltd.

OM nucleic - nucleic search, using sw model

Run on: January 31, 2005, 16:21:35 ; Search time 0.001 Seconds
(without alignments)
91.920 Million cell updates/sec

Title: us-10-063-553-47
Perfect score: 766
Sequence: 1 ggctcgagcgtttctgagcc.....agtagttgaaaaaaaaa 766

Scoring table: IDENTITY_NUC
Gapop 10.0 , Gapext 0.5

Searched: 1 seqs, 60 residues

Total number of hits satisfying chosen parameters: 2

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : abn47584.geneseqn2002as:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	60	7.8	60	1 ABN47584	Human spliced tran
2	9.8	1.3	60	1 ABN47584	Human spliced tran

ALIGNMENTS

RESULT 1
ABN47584
ID ABN47584 standard; DNA; 60 BP.
XX
AC ABN47584;
XX
DT 15-JUL-2002 (first entry)
XX
DE Human spliced transcript detection oligonucleotide SEQ ID NO:20332.
XX
KW Human; mouse; rat; splice transcript; detection; RNA transcript;
KW splice variant; transcriptome; oligonucleotide library; ss.
XX
OS Homo sapiens.
XX
PN WO200210449-A2.
XX
PD 07-FEB-2002.
XX
PF 20-JUL-2001; 2001WO-IB001903.
XX
PR 28-JUL-2000; 2000US-0221607P.
PR 02-MAY-2001; 2001US-0287724P.
XX
PA (COMP-) COMPUGEN INC.

PI Shoshan A, Wasserman A, Mintz E, Mintz L, Faigler S;
XX WPI; 2002-257383/30.
XX
PT New oligonucleotide libraries comprising oligonucleotides which
PT selectively hybridize to mRNAs transcribed from a transcription unit of a
PT genome, useful for detecting tissue-, pathology-, and developmental-
PT specific genes.
XX
PS Example 1; SEQ ID NO 20332; 47pp; English.
XX
CC The present invention describes oligonucleotide libraries for detecting
CC messenger RNAs that populate a (sub-)transcriptome, where the (sub-
CC)transcriptome comprises messenger RNAs transcribed from multiple
CC transcription units that populate a genome. The library comprises several
CC oligonucleotides, each capable of hybridising selectively to a set of
CC messenger RNAs transcribed from a given transcription unit of the genome,
CC which encodes one or more messenger RNA splice variants. The
CC oligonucleotide libraries are useful for detecting mRNAs from a
CC biological sample, in expression profiling studies, in qualitatively or
CC quantitatively characterising the corresponding transcriptome, and in
CC detecting RNA transcripts and splice variants of human or animal
CC transcriptomes. The libraries may also be used as specialised mini
CC libraries to detect transcripts of a sub-transcriptome under a particular
CC biological or pathological state, and so allowing the detection of tissue
CC - and pathology-specific genes such as those genes only expressed in
CC specific tissue under a specific pathological condition; to detect
CC developmental specific genes; and to detect RNA transcripts and splice
CC variants of a transcriptome of a patient suffering from a particular
CC disorder. ABN27253 to ABN59589 represent oligonucleotide sequences from
CC rats, humans and mice, which are used in the exemplification of the
CC present invention. N.B. The sequence data for this patent did not form
CC part of the printed specification, but was obtained in electronic format
CC directly from WIPO at ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 60 BP; 16 A; 14 C; 16 G; 14 T; 0 U; 0 Other;

Query Match 7.8%; Score 60; DB 1; Length 60;
Best Local Similarity 100.0%; Pred. No. 0;
Matches 60; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 513 CAGTAACGACACCATGGCGAGTGGCTGGAGAGCATCTAGTTCCACTTCGATTCTGAAGA 572
Db 1 CAGTAACGACACCATGGCGAGTGGCTGGAGAGCATCTAGTTCCACTTCGATTCTGAAGA 60

RESULT 2
ABN47584/c
ID ABN47584 standard; DNA; 60 BP.
XX
AC ABN47584;
XX
DT 15-JUL-2002 (first entry)
XX
DE Human spliced transcript detection oligonucleotide SEQ ID NO:20332.
XX
KW Human; mouse; rat; splice transcript; detection; RNA transcript;
KW splice variant; transcriptome; oligonucleotide library; ss.
XX
OS Homo sapiens.
XX
PN WO200210449-A2.
XX
PD 07-FEB-2002.
XX
PF 20-JUL-2001; 2001WO-IB001903.
XX
PR 28-JUL-2000; 2000US-0221607P.
PR 02-MAY-2001; 2001US-0287724P.
XX
PA (COMP-) COMPUGEN INC.
XX
PI Shoshan A, Wasserman A, Mintz E, Mintz L, Faigler S;

XX WPI; 2002-257383/30.

DR

XX

PT New oligonucleotide libraries comprising oligonucleotides which

PT selectively hybridize to mRNAs transcribed from a transcription unit of a

PT genome, useful for detecting tissue-, pathology-, and developmental-

PT specific genes.

XX

PS Example 1; SEQ ID NO 20332; 47pp; English.

XX

CC The present invention describes oligonucleotide libraries for detecting

CC messenger RNAs that populate a (sub-)transcriptome, where the (sub-

CC)transcriptome comprises messenger RNAs transcribed from multiple

CC transcription units that populate a genome. The library comprises several

CC oligonucleotides, each capable of hybridising selectively to a set of

CC messenger RNAs transcribed from a given transcription unit of the genome,

CC which encodes one or more messenger RNA splice variants. The

CC oligonucleotide libraries are useful for detecting mRNAs from a

CC biological sample, in expression profiling studies, in qualitatively or

CC quantitatively characterising the corresponding transcriptome, and in

CC detecting RNA transcripts and splice variants of human or animal

CC transcriptomes. The libraries may also be used as specialised mini

CC libraries to detect transcripts of a sub-transcriptome under a particular

CC biological or pathological state, and so allowing the detection of tissue

CC - and pathology-specific genes such as those genes only expressed in

CC specific tissue under a specific pathological condition; to detect

CC developmental specific genes; and to detect RNA transcripts and splice

CC variants of a transcriptome of a patient suffering from a particular

CC disorder. ABN27253 to ABN59589 represent oligonucleotide sequences from

CC rats, humans and mice, which are used in the exemplification of the

CC present invention. N.B. The sequence data for this patent did not form

CC part of the printed specification, but was obtained in electronic format

CC directly from WIPO at ftp.wipo.int/pub/published_pct_sequences

XX

SQ Sequence 60 BP; 16 A; 14 C; 16 G; 14 T; 0 U; 0 Other;

Query Match 1.3%; Score 9.8; DB 1; Length 60;

Best Local Similarity 58.6%; Pred. No. 0;

Matches 17; Conservative 0; Mismatches 12; Indels 0; Gaps 0;

QY 477 CTCTTGTGCACCTCCTACTGGTTTCAATA 505

Db ||||| ||||| ||||| ||||| |||||

32 CTCTCCAGCCACTCGCATGGTGCCTTA 4

Search completed: January 31, 2005, 16:21:35

Job time : 0.001 secs

GenCore version 5.1.6
Copyright (c) 1993 - 2005 Compugen Ltd.

OM nucleic - nucleic search, using sw model

Run on: January 31, 2005, 16:20:13 ; Search time 0.001 Seconds
(without alignments)
162.392 Million cell updates/sec

Title: us-10-063-553-47
Perfect score: 766
Sequence: 1 ggctcgagcgtttctgagcc.....agtagtttgaaaaa 766

Scoring table: IDENTITY_NUC
Gapop 10.0 , Gapext 0.5

Searched: 1 seqs, 106 residues
Total number of hits satisfying chosen parameters: 2

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : abs72969.geneseqn2002as.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	70	9.1	106	1 ABS72969	Human gene trapped
2	15.8	2.1	106	1 ABS72969	Human gene trapped

ALIGNMENTS

RESULT 1	
ABS72969	
ID ABS72969 standard; cDNA; 106 BP.	
XX	
AC ABS72969;	
XX	
DT 03-DEC-2002 (first entry)	
XX	
DE Human gene trapped sequence (GTS) #929.	
XX	
KW Human; gene trapped sequence; GTS; gene; ss; cancer; autoimmune disease;	
KW lupus; scleroderma; Crohn's disease; multiple sclerosis; immune disorder;	
KW inflammatory bowel disease; schizophrenia; psychosis; osteoarthritis;	
KW inflammatory disorder; diabetes; skin disorder; acne; eczema; asthma;	
KW rheumatoid arthritis; hypertension; atherosclerosis; Alzheimer's disease;	
KW cardiovascular disease; Parkinson's disease; osteoporosis; infertility;	
KW viral infection; parasitic infection; fungal infection;	
KW bacterial infection; forensic analysis; cellular differentiation.	
XX	
OS Homo sapiens.	
XX	
PN US2002095031-A1.	
XX	
PD 18-JUL-2002.	
XX	
PF 03-MAY-2000; 2000US-00563817.	

XX	04-MAY-1999; 99US-0132343P.
PR	
XX	(NEHL/) NEHLS M C.
PA	(ZAMB/) ZAMBROWICZ B.
PA	(SAND/) SANDS A T.
XX	
PI	Nehls MC, Zambrowicz B, Sands AT;
XX	
DR	WPI; 2002-656030/70.
XX	
PT	New isolated or purified human gene trapped sequences, useful for gene
PT	discovery, as markers for gene expression analysis, identifying and
PT	mapping the coding regions of human genome, or determining the genetic
PT	basis of human disease.
XX	
PS	Claim 1; SEQ ID NO 937; 36pp; English.
XX	
CC	The invention relates to isolated or purified polynucleotides that
CC	correspond to human gene trapped sequences (GTSS). The human GTSS are
CC	useful for gene discovery and as markers for gene expression analysis,
CC	for identifying and mapping the coding regions of the mammalian,
CC	particularly human, genome, for forensic analysis, and for determining
CC	the genetic basis of human disease. The peptides and proteins encoded by
CC	the polynucleotides are useful for generating antibodies, as reagents in
CC	diagnostic assays and in identifying other cellular gene products
CC	involved in the regulation of development and cellular differentiation of
CC	various cell types. The peptides are also useful as reagents in assays
CC	for screening of compounds used in treating disorders affecting
CC	development and cell differentiation. The GTSS are also useful in
CC	treating or ameliorating diseases associated with the expression of
CC	mutant or normal variants of the GTSS, e.g. cancer, autoimmune diseases,
CC	lupus, scleroderma, Crohn's disease, multiple sclerosis, inflammatory
CC	bowel disease, immune disorders, schizophrenia, psychosis, inflammatory
CC	disorders, diabetes, skin disorders such as acne or eczema,
CC	osteoarthritis, rheumatoid arthritis, hypertension, atherosclerosis,
CC	cardiovascular diseases, Alzheimer's disease, Parkinson's disease,
CC	osteoporosis, asthma, infertility, and viral, parasitic, fungal or
CC	bacterial infections. This sequence represents a human GTS of the
CC	invention
XX	
SQ	Sequence 106 BP; 26 A; 21 C; 28 G; 26 T; 0 U; 5 Other;

Query Match 9.1%; Score 70; DB 1; Length 106;
Best Local Similarity 88.7%; Pred. No. 0;
Matches 94; Conservative 0; Mismatches 10; Indels 2; Gaps 2;

QY	236	CCTTGACAGCAAGAAAAAGAGCGTGTGCAACACAGAACTGGAATGTTCTTTCAT-CA 294
Db	1	CCTTGACAGCAGGAAAAAGAGCGGTGTCNACANCAAGAACTGGAATGTTTTCATGCA 60
QY	295	TTTTTTCAGTGTGA-TCACAGTCATTGCTGCTCTGTATTGTCATGCTG 339
Db	61	CTTTTCAGTGNAGACACAGTCATTCGNGCTCTGTATTGTCATGCTG 106

RESULT 2
ABS72969/c
ID ABS72969 standard; cDNA; 106 BP.

XX
AC ABS72969;
XX
DT 03-DEC-2002 (first entry)
XX
DE Human gene trapped sequence (GTS) #929.

XX
KW Human; gene trapped sequence; GTS; gene; ss; cancer; autoimmune disease;
KW lupus; scleroderma; Crohn's disease; multiple sclerosis; immune disorder;
KW inflammatory bowel disease; schizophrenia; psychosis; osteoarthritis;
KW inflammatory disorder; diabetes; skin disorder; acne; eczema; asthma;
KW rheumatoid arthritis; hypertension; atherosclerosis; Alzheimer's disease;
KW cardiovascular disease; Parkinson's disease; osteoporosis; infertility;
KW viral infection; parasitic infection; fungal infection;

bacterial infection; forensic analysis; cellular differentiation.

Homo sapiens.

US2002095031-A1.

18-JUL-2002.

03-MAY-2000; 2000US-00563817.

04-MAY-1999; 99US-0132343P.

(NEHL/) NEHLS M C.

(ZAMB/) ZAMBROWICZ B.

(SAND/) SANDS A T.

Nehls MC, Zambrowicz B, Sands AT;

WPI; 2002-656030/70.

New isolated or purified human gene trapped sequences, useful for gene discovery, as markers for gene expression analysis, identifying and mapping the coding regions of human genome, or determining the genetic basis of human disease.

Claim 1; SEQ ID NO 937; 36pp; English.

The invention relates to isolated or purified polynucleotides that correspond to human gene trapped sequences (GTSs). The human GTSs are useful for gene discovery and as markers for gene expression analysis, for identifying and mapping the coding regions of the mammalian, particularly human, genome, for forensic analysis, and for determining the genetic basis of human disease. The peptides and proteins encoded by the polynucleotides are useful for generating antibodies, as reagents in diagnostic assays and in identifying other cellular gene products involved in the regulation of development and cellular differentiation of various cell types. The peptides are also useful as reagents in assays for screening of compounds used in treating disorders affecting development and cell differentiation. The GTSs are also useful in treating or ameliorating diseases associated with the expression of mutant or normal variants of the GTSs, e.g. cancer, autoimmune diseases, lupus, scleroderma, Crohn's disease, multiple sclerosis, inflammatory bowel disease, immune disorders, schizophrenia, psychosis, inflammatory disorders, diabetes, skin disorders such as acne or eczema, osteoarthritis, rheumatoid arthritis, hypertension, atherosclerosis, cardiovascular diseases, Alzheimer's disease, Parkinson's disease, osteoporosis, asthma, infertility, and viral, parasitic, fungal or bacterial infections. This sequence represents a human GTS of the invention

Sequence 106 BP; 26 A; 21 C; 28 G; 26 T; 0 U; 5 Other;

Query Match 2.1%; Score 15.8; DB 1; Length 106;

Best Local Similarity 74.1%; Pred. No. 0;

Matches 20; Conservative 0; Mismatches 7; Indels 0; Gaps 0;

69 CAGCCTGCTGGTCTACTGCTGTAGG 95

||||| ||| ||| ||| ||| |||

28 CAGCCCGCTCTTTTCTCGTGTCAAG 2

Search completed: January 31, 2005, 16:20:13
Job time : 0.001 secs